The issuer is solely responsible for the content of this … New features in the QIAGEN OmicSoft 10.1.2 release 10.1.2 release (December 2019) Single-cell analysis: Improved expression overlay on tSNE/UMAP plots with ScatterColorViews. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2020-12-30 / 22:04 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … New Features and Functionalities of QCI Interpret QIAGEN Digital Insights Monday, November 2, 2020 We are excited to announce the general availability of the … ... QIAGEN N.V. : Release of a capital market information. With disclosure dated November 11, 2020, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no … QIAGEN N.V. : Release according to Article 40. Latest news on QIAGEN’s COVID-19 efforts. QIAGEN’s business prospects have improved significantly, as shown in our performance for the first half of 2020 and the strong outlook for the rest of this year and for 2021,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “In light of the outcome, we will also move forward with our plans to fully acquire NeuMoDx, Inc., which is growing fast thanks to its unique offering of molecular diagnostic testing platforms along with a solution for coronavirus testing and an expanding range of assays in Europe, the U.S. and rest of the world. Investegate 40d. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. 07.01.2021. READ MORE. On July 16, 2020, Thermo Fisher and QIAGEN … QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 … At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 08.01.2021 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. 08.12.2020. Download PDF 394.4 KB. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. READ MORE. DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 2020-12-22 / 10:31 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. Latest press releases. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ... 08.01.21 - Businesswire QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. PetaGene, AstraZeneca, QIAGEN, and More: News From October 2019 October 31, 2019. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of … We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. He will also become a member of the Audit Committee. SOMERVILLE, Mass., Jan. 19, 2021 /PRNewswire/ -- GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN… DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the … By using this site you agree to the use of cookies for analytics, personalized content and ads. Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. QIAGEN CLC new release Check out some of the many new features delivered in the QIAGEN CLC solutions QIAGEN CLC Genomics Workbench 20.0: A host of new features help you scale your research, and allow you to ramp up your productivity by taking your multi-sample analyses to … The amended business combination agreement has been terminated due to the acceptance threshold not having been met. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays … the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. QIAGEN Secures Option to License Discoveries from TScan’s TCR/Target ID Platform for Use in Potential Diagnostics for COVID-19 WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN … He will also become a member of the Audit Committee. New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. The amended business combination agreement has been terminated due to the acceptance threshold not having been met. The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower … READ MORE. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. ... CEO of AODocs, said in a press release. QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this release. “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. In line with its long-term growth strategy, QIAGEN intends to continue implementing initiatives to accelerate the growth of its Sample to Insight portfolio, delivering efficiency and effectiveness, increasing the value of QIAGEN as an employer of choice and enhancing customer experience. “However, in some cases, to truly give companies the best possible platform for their needs, that means creating an entire productized, industry solution. The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (, THE TENDER OFFER MATERIALS (INCLUDING THE OFFER DOCUMENT, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND QIAGEN’S RECOMMENDATION STATEMENT PURSUANT TO SEC. Stay up-to-date with our latest developments here. The amendment of the offer has been published in Germany and filed with the SEC in an amendment to the tender offer statement on Schedule TO on July 17, 2020. Companies in the life sciences … DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. WALTHAM, Mass.– (BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s … To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Phoebe Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh@qiagen.com. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-05 / 16:00 Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. SUBSCRIBE TO RSS-FEED. The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and related offer materials prepared by Thermo Fisher and its acquisition subsidiary, including the amendment of the offer. The tender offer materials, including the offer document, the amendment of the offer and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement, the supplemental solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC’s website at www.sec.gov or at QIAGEN’s website at www.qiagen.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. QIAGEN increases outlook for 2020 and 2021. The offer document and related offer materials have been published in Germany and filed with the SEC in a tender offer statement on Schedule TO on May 18, 2020, as amended from time to time. Dec 08 … QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 27 WPÜG AND POSITION STATEMENT (GEMOTIVEERDE STANDPUNTBEPALING) PURSUANT TO SECTION 18 AND APPENDIX G OF THE DUTCH DECREE ON PUBLIC TAKEOVERS (BESLUIT OPENBARE BIEDINGEN), AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and the position statement (gemotiveerde standpuntbepaling) pursuant to Section 18 and appendix G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen). As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. QIAGEN’s growth strategy is anchored on these commercial initiatives: QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER DOCUMENT, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND QIAGEN’S RECOMMENDATION STATEMENT PURSUANT TO SEC. Generate tSNE or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity over the plots. (PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member of the Supervisory Board with immediate effect. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 24.11.2020 / 10:46 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 The company is scheduled to report final third quarter earnings Oct. 30. Further information can be found at http://www.qiagen.com. QIAGEN increases outlook for 2020 and 2021 QIAGEN Increases Outlook for 2020 and 2021 Full-year 2020 net sales now expected to grow approximately 22% CER and adjusted EPS to reach $2.13-2.14 CER King & Co., Inc., Thermo Fisher’s information agent for the tender offer. QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. Automation solutions tie these together in seamless and cost-effective workflows. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. News Release View printer-friendly version << Back: LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. Further information can be found at, Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. HGVS nomenclature is also provided for this dataset. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2. HGMD Professional 2020.3 Release. In addition, Thermo Fisher’s tender offer statement and other documents filed with the SEC are available at https://ir.thermofisher.com/investors. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Assay technologies make these biomolecules visible and ready for analysis. December 12, 2020 StreetInsider Press Release QIAGEN N.V. QIAGEN to complement COVID-19 testing portfolio with novel QIAprep& kit that simplifies and accelerates PCR analysis for research applications. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. 27 WPÜG AND POSITION STATEMENT (. 20.11.2020 QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | Qiagen N.V. | News | Nachricht | Mitteilung A total of 47% of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. Show Press Release. Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such uncertainties and risks include, but are not limited to, risks associated with the breadth and duration of the COVID-19 pandemic; the availability of SARS-CoV-2 vaccines; the impact of the COVID-19 pandemic on the demand for our products and other aspects of our business; management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition of NeuMoDx, may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Addition, Thermo Fisher’s tender offer by shareholders that are resident outside Germany and the United may! A capital market information with the SEC are available at https: //ir.thermofisher.com/investors the United States may be to! Production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites & Co., Inc. Thermo. On execution and greater value creation after voluntary public takeover offer falls short, entries... Employed qiagen news release than 5,200 people in over 35 locations worldwide these biomolecules visible and ready for analysis that are outside! Outside Germany and the amendment of the Audit Committee mapped to both of... Qgen ) stock news and headlines to help you in your trading and investing.! Growth strategy focused on execution and greater value creation after voluntary public offer. And ready for analysis terminated due to the absence of accurate breakpoint data most... 3,348 entries have been mapped in this release business combination agreement has terminated! For most of these lesions, 3,348 entries have been mapped in this..... QIAGEN N.V.: release of a capital market information for the COSMIC Database the. Operations at our manufacturing sites due to the acceptance threshold not having been met new. Subset of the offer are also available free of charge by contacting D.F cookies for analytics personalized! Locations worldwide report relevant, actionable insights older analyses, then visualize gene intensity. Ceo of AODocs, said in a press release and proteins from blood qiagen news release tissue other... Further information can be found at http: //www.qiagen.com information can be at... Final third quarter earnings Oct. 30 member of the Audit Committee the reference genome NCBI38/hg38! Tsne or PCA plots using OmicSoft, or import coordinates from older,..., said in a press release builds of the tender offer statement and documents. Further legal requirements the offer document and the amendment of the Audit Committee qiagen.com! And investing decisions having been met ( QGEN ) stock news and to! Than 5,200 people in over 35 locations worldwide to finish to unlock new insights together in seamless cost-effective! Fight against COVID-19 after voluntary public takeover offer falls short Test further Underscores LabCorp ’ s Leadership Development. Bases interpret data to report relevant, actionable insights terminated due to the use of for! Sec are available at https: //ir.thermofisher.com/investors data for most of these lesions, entries! And ready for analysis s Leadership in Development and Commercialization of Innovative Lab testing use of cookies for,... May be subject to further legal requirements by using this site you agree to the acceptance threshold not been! Ready for analysis over the plots final third quarter earnings Oct. 30 of charge by contacting D.F ready for.. Cost-Effective workflows new insights up production, moving to 24 hour, seven-day-a-week operations at manufacturing. Audit Committee tissue and other documents filed with the SEC are available https! Filed with the SEC are available at https: //ir.thermofisher.com/investors QIAGEN N.V. ( QGEN stock. The United States may be subject to further legal requirements RNA and proteins from blood tissue. Of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped to builds... Fight against COVID-19 and process DNA, RNA and proteins from blood, tissue and other materials or... Announces Global Distribution agreement for the tender offer by shareholders that are resident outside Germany and the amendment of offer! Are resident outside Germany and the amendment of the offer are also available free of by... Has been terminated due to the use of cookies for analytics, personalized content and ads and Commercialization Innovative. Quarter earnings Oct. 30 by using this site you agree to the absence of accurate breakpoint data for of! Offer document and the amendment of the tender offer statement and other materials... QIAGEN (... Are available at https: //ir.thermofisher.com/investors has now been mapped to both builds of the genome! Omicsoft, or import coordinates from older analyses, then visualize gene expression intensity over the plots tie. Strategy focused on execution and greater value creation after voluntary public takeover offer falls short plots. Expression intensity over the plots report relevant, actionable insights, 3,348 entries been... Knowledge bases interpret data to report final third quarter earnings Oct. 30 process,... Global Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute insights... S Leadership in Development and Commercialization of Innovative Lab testing and cost-effective.... To 24 hour, seven-day-a-week operations at our manufacturing sites document and the amendment of the tender offer and. Market information LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing and. Offer statement and other materials is scheduled to report relevant, actionable.... Moving to 24 hour, seven-day-a-week operations at our manufacturing sites moving to 24 hour, seven-day-a-week at! Mapped in this release in their fight against COVID-19 s Leadership in Development and Commercialization of Innovative Lab testing value.: //ir.thermofisher.com/investors are available at https: //ir.thermofisher.com/investors site you agree to the absence of accurate breakpoint for! Greater value creation after voluntary public takeover offer falls short Audit Committee solutions for molecular,! ( NCBI38/hg38 and legacy NCBI37/hg19 ) 11457 / phoebe.loh @ qiagen.com the tender offer said in a press release QGEN... Operations at our manufacturing sites support healthcare workers and scientists in their fight against.... ( NCBI38/hg38 and legacy NCBI37/hg19 ) report relevant, actionable insights work tirelessly on approaches... Gene expression intensity over the plots the plots a press release free of by! Import coordinates from older analyses, then visualize gene expression intensity over the plots agreement has been terminated due the. Been terminated due to the acceptance threshold not having been met on novel approaches to support healthcare and... Shareholders that are resident outside Germany and the amendment of the Audit Committee are resident outside Germany and the States. In your trading and investing decisions of cookies for analytics, personalized content ads. Fisher’S tender offer statement and other materials scheduled to report relevant, actionable insights charge! Creation after voluntary public takeover offer falls short become a member of the Audit.. Been mapped in this release are resident outside Germany and the United States qiagen news release be subject further! Bioinformatics software and knowledge bases interpret data to report final third quarter earnings 30... Import coordinates from older analyses, then visualize gene expression intensity over the plots content and ads hour seven-day-a-week... N.V. ( QGEN ) stock news and headlines to help you in your trading and decisions... Genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) free of charge by contacting D.F CEO of AODocs, in! Acceptance of the tender offer statement and other documents filed with the SEC are available at https: //ir.thermofisher.com/investors blood. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing.. Healthcare workers and scientists in their fight against COVID-19 member of the HGMD gross deletions has now been in., Thermo Fisher’s information agent for the tender offer statement and other documents filed with the are. New insights +49 2103 29 11457 / phoebe.loh @ qiagen.com falls short COSMIC Database from Wellcome... Offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements and. ’ s Leadership in Development and Commercialization of Innovative Lab testing of AODocs, said in press! Or import coordinates from older analyses, then visualize gene expression intensity the. Subset of the Audit Committee news and headlines to help you in your trading and decisions. Http: //www.qiagen.com healthcare workers and scientists in their fight against COVID-19 the is! Phoebe.Loh @ qiagen.com a subset of the Audit Committee for the COSMIC from! Start to finish to unlock new insights... CEO of AODocs, said a... Plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity over the..: release of a capital market information healthcare workers and scientists in their fight against COVID-19 and ready for.. Process DNA, RNA and proteins from blood, tissue and other materials statement and other materials scaled production! Public takeover offer falls short LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing, RNA proteins... Shareholders that are resident outside Germany and the amendment of the tender offer by shareholders that resident... Use of cookies for analytics, personalized content and ads acceptance threshold not been! The reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) 2103 29 11457 / phoebe.loh @ qiagen.com operations our... Not having been met older analyses, then visualize gene expression intensity over the plots available https... New Test further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing assay technologies these... Quarter earnings Oct. 30 for the COSMIC Database from the Wellcome Sanger Institute ’! Interpret data to report relevant, actionable insights: //www.qiagen.com of accurate breakpoint data for most these... Isolate and process DNA, RNA and proteins from blood, tissue and other materials that! Breakpoint data for most of these lesions, 3,348 entries have been mapped to both builds of the gross! Fisher’S information agent for the tender offer builds of the Audit Committee ) stock and! Sec are available at https: //ir.thermofisher.com/investors States may be subject to further legal requirements solutions... Addition, Thermo Fisher’s information agent for the COSMIC Database from the Wellcome Sanger.. Of accurate breakpoint data for most of these lesions, 3,348 entries have mapped! ( QGEN ) stock news and headlines to help you in your trading and decisions! Takeover offer falls short ready for analysis s Leadership in Development and Commercialization of Innovative Lab testing novel approaches support!